Study: rare GLP1R gene variants blunt weight loss on semaglutide but not tirzepatide
_Image credit: Nature Metabolism_
Using exome sequencing and health records for 13,725 US adults on weekly injections, Helix researchers found that the roughly 0.2% carrying rare damaging GLP1R variants lost about 2.4% of body weight on semaglutide versus 8.8% for matched non-carriers, while carriers on tirzepatide lost 13.3% versus 15.2%. Carrier numbers are small, but the authors suggest such patients may do better on drugs that also act on other receptors.
Source: Nature Metabolism (11 Nov 2026). Image: Nature Metabolism.